Pain market

Nature Reviews Drug Discovery

Volumn 9, Issue 8, 2010, Pages 589-590

  Melnikova, Irena ^a  

^a TVM Capital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACUROX; AMG 403; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIULCER AGENT; CYCLOOXYGENASE 2 INHIBITOR; DUEXA; DULOXETINE; EMBEDA; ESOMEPRAZOLE PLUS NAPROXEN; FAMOTIDINE PLUS IBUPROFEN; JNJ 42160443; MILNACIPRAN; MORPHINE PLUS NALTREXONE; NERVE GROWTH FACTOR ANTIBODY; NEUBLASTIN; NIACIN PLUS OXYCODONE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; OXYCODONE; PARACETAMOL; PREGABALIN; REGN 475; SAR 164877; SAVELLA; SLC 022; TANEZUMAB; UNCLASSIFIED DRUG; VIMOVO;

CHRONIC PAIN; CLINICAL TRIAL; COST OF ILLNESS; DIGESTIVE SYSTEM ULCER; DRUG APPROVAL; DRUG DEPENDENCE; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; ECONOMIC DEVELOPMENT; FIBROMYALGIA; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; LOW BACK PAIN; NEUROPATHIC PAIN; PAIN; PREVALENCE; PRIORITY JOURNAL; RESPIRATION DEPRESSION; SHORT SURVEY; TREATMENT INDICATION; UNITED STATES;

ANALGESICS; COMMERCE; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MARKETING; PAIN;

EID: 77955172408     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3226     Document Type: Short Survey

References (4)

1. Harstall, C. How prevalent is chronic pain?Pain Clinical Updates X, 1-4 (2003).
2. Woodcock, J. A difficult balance\pain management,drug safety, and the FDA. N. Engl. J. Med. 361,2105-2107 (2009).
3. Dworkin, R. H. et al. Recommendations for thepharmacological management of neuropathic pain. Mayo Clin. Proc. 85 (Suppl. 3), 3-14 (2010).
4. Arnold, L. M. Strategies for managing fibromyalgia. Am. J. Med. 122 (Suppl. 12), 31-43 (2009).